CRSP FY2025 EPS Estimate Raised by Cantor Fitzgerald

CRISPR Therapeutics AG (NASDAQ:CRSP) – Cantor Fitzgerald upped their FY2025 earnings estimates for CRISPR Therapeutics in a note issued to investors on Wednesday, May 7th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will earn ($6.71) per share for the year, up from their prior estimate of ($6.91). Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

Several other equities research analysts have also recently weighed in on CRSP. Chardan Capital lowered their target price on CRISPR Therapeutics from $84.00 to $82.00 and set a “buy” rating for the company in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Friday, March 21st. Stifel Nicolaus lowered their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. Finally, JMP Securities reissued a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $71.75.

CRISPR Therapeutics Stock Down 1.4 %

Shares of NASDAQ:CRSP opened at $35.62 on Friday. The business’s 50 day moving average is $38.15 and its 200 day moving average is $42.75. The stock has a market cap of $3.08 billion, a P/E ratio of -8.15 and a beta of 1.88. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same quarter in the previous year, the firm earned ($1.43) earnings per share. The company’s revenue was up 71.6% compared to the same quarter last year.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds have recently made changes to their positions in the company. ARK Investment Management LLC grew its stake in CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after purchasing an additional 1,474,439 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after buying an additional 1,074,238 shares during the last quarter. Capital International Investors increased its holdings in CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after buying an additional 816,789 shares during the period. Baker BROS. Advisors LP raised its position in CRISPR Therapeutics by 55.1% during the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company’s stock worth $51,483,000 after buying an additional 464,936 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $17,458,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at CRISPR Therapeutics

In related news, Director John Greene bought 7,000 shares of the company’s stock in a transaction on Wednesday, February 26th. The shares were bought at an average price of $44.85 per share, with a total value of $313,950.00. Following the transaction, the director now owns 7,000 shares in the company, valued at approximately $313,950. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,381 shares of company stock worth $1,608,243. 4.30% of the stock is owned by insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.